Business Week
Questions for Amgen's Roger Perlmutt
How is the FDA Progressing with it’s Risk-based Approach to Compliance?
QUMAS: FDA's Progress with Risk-based Approach to Compliance
BELGIUM/FILE: European court to rule whether Microsoft abused its near-monopoly position on the world's computer market
INDEPENDENT MEDIA IN A TIME OF WAR 1 OF 2
The Longevity Factor: Joseph Maroon
Joe McCracken, VP of Business Development, Genentech
Previous Page
Next Page
Questions for Amgen's Roger Perlmutt
From collaboration to consolidation, competition to contractual concerns, these five questions from BusinessWeek readers cut to the heart of what’s important in the pharmaceutical industry
Business Week | November 12, 2008
